MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/spv.0000000000001190

Медицинская библиотека · Female pelvic medicine & reconstructive surgery · 2022

Adverse Events for Overactive Bladder Medications From a Public Federal Database.

Sze Christina, Drangsholt Siri, Stoddard Michelina D, Singh Zorawar, Sansone Stephanie, Bhojani Naeem, Zorn Kevin, Elterman Dean, Chughtai Bilal

СтатьяПеревод в очереди

Аннотация

IMPORTANCE

Clinical data on the use of overactive bladder (OAB) medications are limited by the physician interpretation of adverse effects rather than those that are patient reported.

OBJECTIVE

The aim of the study was to evaluate the association between OAB medications and adverse drug events (ADEs) through the self-reporting U.S. Food and Drug Administration Adverse Event Report System database.

STUDY

DESIGN

The U.S. Food and Drug Administration Adverse Event Report System (FAERS) database was queried from 2004 to 2019. Adverse drug events were recategorized. Disproportionality analysis was used to detect the risk signals for each OAB medication and ADEs. χ 2 values were calculated to assess the association between ADEs and dosage.

RESULTS

A total number of 14,102 reports were identified. The most frequently reported OAB medications were mirabegron (35%), transdermal oxybutynin (27%), and solifenacin (25%). Neuropsychiatric (NP) ADEs were highest with tolterodine and fesoterodine usage (16% and 15.6%, respectively) and transdermal oxybutynin had the lowest (6.5%). Increasing the dose of tolterodine or fesoterodine was not associated with increased NP ADEs. Oxybutynin had the highest risk of affect/mood disorder, agitation, and balance/movement disorder; however, it had the lowest risk of headache/migraine compared with all OAB medications. Mirabegron compared with all other OAB medications had the lowest risk of affect/mood disorder and agitation; however, it had the highest risk of headache and migraines.

CONCLUSIONS

The FAERS database not only is a repository of ADEs but also may represent evolving prescribing habits for OAB medications. Transdermal oxybutynin had the lowest NP ADEs and may be appropriate for selected individuals.

Для цитирования: Sze Christina, Drangsholt Siri, Stoddard Michelina D, Singh Zorawar, Sansone Stephanie, Bhojani Naeem, Zorn Kevin, Elterman Dean, Chughtai Bilal. Adverse Events for Overactive Bladder Medications From a Public Federal Database.. Female pelvic medicine & reconstructive surgery. 2022. DOI: 10.1097/spv.0000000000001190.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.